Tonazocine
![]()  | |
![]()  | |
| Clinical data | |
|---|---|
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H35NO2 | 
| Molar mass | 357.538 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain,[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter.[2][3] It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations (probably via binding to and activating the κ-opioid receptor).[4]
See also
References
- ↑ American Chemical Society. Division of Medicinal Chemistry (1990). Annual Reports in Medicinal Chemistry. Academic Press. p. 12. ISBN 978-0-12-040525-1. Retrieved 30 November 2011.
 - ↑ Ward SJ, Pierson AK, Michne WF (February 1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides. 5 (4–6): 375–8. doi:10.1016/0143-4179(85)90032-0. PMID 2860595. S2CID 20674308.
 - ↑ Hudzik TJ, Howell A, Payza K, Cross AJ (May 2000). "Antiparkinson potential of delta-opioid receptor agonists". European Journal of Pharmacology. 396 (2–3): 101–7. doi:10.1016/S0014-2999(00)00209-0. PMID 10822062.
 - ↑ Aronson, Jeffrey K. (30 November 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 154. ISBN 978-0-444-53273-2. Retrieved 30 November 2011.
 
| Psychedelics (5-HT2A agonists)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists)  | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others | 
  | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Opioid receptor modulators  | |||||
|---|---|---|---|---|---|
| μ-opioid (MOR)  | 
  | ||||
| δ-opioid (DOR)  | 
  | ||||
| κ-opioid (KOR)  | 
  | ||||
| Nociceptin (NOP)  | 
  | ||||
| Others | 
 
 
  | ||||
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

